CytomX Therapeutics Company Profile
CytomX Therapeutics is an early stage biotechnology company developing Probodies™, or proteolytically-activated antibodies. Probodies combine the well-established power and specificity of monoclonal antibodies with a second level of tissue selectivity, driven by the action of endogenous disease enzymes. Probodies, by their ability to site-direct the activity of antibodies, will result in an improved therapeutic index for validated targets as well as enable the drugging of targets with broad tissue expression. The company’s mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases. For more information, please visit www.cytomx.com.
News Articles
CytomX Therapeutics Adds $11M For Antibody Drugs
South San Francisco-based CytomX Therapeutics has an ambitious plan to make an antibody drug that can beat existing products from Eli Lilly and Amgen. Now it has some more money to pursue the goal. Cy...
CytomX Therapeutics expands Series B financing
CytomX Therapeutics has expanded its Series B financing, bringing the total size of the round to $41 million. Canaan Partners led the financing and was joined by existing investors Third Rock Ventures...
CytomX raises $11M in series B extension
CytomX Therapeutics Inc. (South San Francisco, Calif.) raised $11 million in an extension of a series B round, bringing the total raised in the round to $41 million. New investor Canaan Partners led t...
CytomX Therapeutics, Inc., a biotechnology company developing a new generation of highly targeted antibody therapeutics, today announced that data highlighting the companyâ...
CytomX board of directors update
CytomX Therapeutics Expands Series B Financing; Canaan Partners Joins Syndicate
CytomX Therapeutics, Inc., a biotechnology company creating a new generation of highly targeted antibody therapeutics, today announced that the company has expanded its Series B f...
CytomX Therapeutics Named a Finalist for the 2013 Red Herring Top 100 North America Award
CytomX Therapeutics, a biotechnology company developing a new generation of highly targeted antibody therapeutics, announced today it has been selected as a finalist...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
CytomX Therapeutics is a biotechnology company focused on revolutionizing the monoclonal antibody field by creating a new generation of highly targeted antibody therapeutics. Cyto...
CytomX Therapeutics is an early stage biotechnology company developing Probodies™, or proteolytically-activated antibodies. Probodies combine the well-established power and s...
More Information about "CytomX Therapeutics" on BioPortfolio
We have published hundreds of CytomX Therapeutics news stories on BioPortfolio along with dozens of CytomX Therapeutics Clinical Trials and PubMed Articles about CytomX Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CytomX Therapeutics Companies in our database. You can also find out about relevant CytomX Therapeutics Drugs and Medications on this site too.
